NASDAQ:KPTI Karyopharm Therapeutics (KPTI) Stock Price, News & Analysis → America’s worst nightmare? (From Porter & Company) (Ad) Free KPTI Stock Alerts $1.12 +0.03 (+2.75%) (As of 05/13/2024 ET) Add Compare Share Share Today's Range$1.07▼$1.1550-Day Range$1.02▼$1.5852-Week Range$0.62▼$2.67Volume1.05 million shsAverage Volume1.58 million shsMarket Capitalization$131.84 millionP/E RatioN/ADividend YieldN/APrice Target$4.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Karyopharm Therapeutics alerts: Email Address Karyopharm Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside328.6% Upside$4.80 Price TargetShort InterestBearish14.59% of Shares Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment0.33Based on 26 Articles This WeekInsider TradingSelling Shares$197,094 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.25) to ($0.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.05 out of 5 starsMedical Sector528th out of 2,771 stocksPharmaceutical Preparations Industry212th out of 1,288 stocks 3.3 Analyst's Opinion Consensus RatingKaryopharm Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageKaryopharm Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Karyopharm Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.59% of the outstanding shares of Karyopharm Therapeutics have been sold short.Short Interest Ratio / Days to CoverKaryopharm Therapeutics has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.Change versus previous monthShort interest in Karyopharm Therapeutics has recently decreased by 27.12%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKaryopharm Therapeutics does not currently pay a dividend.Dividend GrowthKaryopharm Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKaryopharm Therapeutics has received a 71.09% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Other cancer medication", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Karyopharm Therapeutics is -1.11. Previous Next 2.4 News and Social Media Coverage News SentimentKaryopharm Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Karyopharm Therapeutics this week, compared to 2 articles on an average week.Search Interest5 people have searched for KPTI on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Karyopharm Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $197,094.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Karyopharm Therapeutics is held by insiders.Percentage Held by Institutions66.44% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Karyopharm Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($1.25) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karyopharm Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karyopharm Therapeutics is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Karyopharm Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingREAD THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. About Karyopharm Therapeutics Stock (NASDAQ:KPTI)Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.Read More KPTI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KPTI Stock News HeadlinesMay 13 at 3:34 AM | americanbankingnews.comQ3 2024 Earnings Forecast for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Issued By Leerink PartnrsMay 13 at 3:34 AM | americanbankingnews.comKaryopharm Therapeutics Inc. to Post Q3 2024 Earnings of ($0.31) Per Share, HC Wainwright Forecasts (NASDAQ:KPTI)May 13 at 2:50 AM | americanbankingnews.comKaryopharm Therapeutics' (KPTI) "Buy" Rating Reaffirmed at HC WainwrightMay 10, 2024 | seekingalpha.comKPTI Karyopharm Therapeutics Inc.May 10, 2024 | markets.businessinsider.comBuy Rating for Karyopharm Therapeutics: Debt Restructuring and Promising Xpovio Studies Drive Optimistic OutlookMay 10, 2024 | finance.yahoo.comKaryopharm Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 9, 2024 | markets.businessinsider.comOptimistic Buy Rating for Karyopharm Therapeutics Amidst Financial Stability and Promising Clinical TrialsMay 9, 2024 | finance.yahoo.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comKaryopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 8, 2024 | finance.yahoo.comQ1 2024 Karyopharm Therapeutics Inc Earnings CallMay 8, 2024 | finanznachrichten.deKaryopharm Therapeutics Inc.: Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressMay 8, 2024 | finance.yahoo.comKaryopharm Therapeutics Reports Q1 2024 Financial Results: A Detailed ReviewMay 8, 2024 | markets.businessinsider.comKaryopharm Therapeutics Inc. Q1 Loss increases, but beats estimatesMay 8, 2024 | prnewswire.comKaryopharm to Participate at the 2024 RBC Capital Markets Global Healthcare ConferenceMay 8, 2024 | investorplace.comKPTI Stock Earnings: Karyopharm Therapeutics Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | prnewswire.comKaryopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029May 8, 2024 | prnewswire.comKaryopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressMay 2, 2024 | prnewswire.comKaryopharm to Report First Quarter 2024 Financial Results on May 8, 2024May 1, 2024 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 24, 2024 | prnewswire.comKaryopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual MeetingApril 1, 2024 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 15, 2024 | finance.yahoo.comKPTI Apr 2024 5.000 callMarch 15, 2024 | finance.yahoo.comKPTI Apr 2024 1.500 putMarch 14, 2024 | businesswire.comOnco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO ® (selinexor)March 6, 2024 | finance.yahoo.comKaryopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma ConferencesSee More Headlines Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/13/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KPTI CUSIPN/A CIK1503802 Webwww.karyopharm.com Phone(617) 658-0600FaxN/AEmployees325Year FoundedN/APrice Target and Rating Average Stock Price Target$4.80 High Stock Price Target$8.00 Low Stock Price Target$3.00 Potential Upside/Downside+328.6%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-143,100,000.00 Net Margins-104.18% Pretax Margin-103.94% Return on EquityN/A Return on Assets-57.80% Debt Debt-to-Equity RatioN/A Current Ratio3.04 Quick Ratio2.99 Sales & Book Value Annual Sales$146.03 million Price / Sales0.90 Cash FlowN/A Price / Cash FlowN/A Book Value($1.19) per share Price / Book-0.94Miscellaneous Outstanding Shares117,710,000Free Float112,648,000Market Cap$131.84 million OptionableOptionable Beta0.16 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Richard A. Paulson M.B.A. (Age 57)President, CEO & Director Comp: $1.43MMs. Sohanya Cheng M.B.A. (Age 41)Executive VP & Chief Commercial Officer Comp: $742.95kMr. Stuart PoultonExecutive VP & Chief Development OfficerDr. Reshma Rangwala M.D. (Age 46)Ph.D., Executive VP, Chief Medical Officer & Head of Research Comp: $777.32kDr. Mansoor Raza Mirza M.D. (Age 63)Clinical Consultant, Member of Scientific Advisory Board & Independent Director Comp: $150kDr. Sharon Shacham M.B.A. (Age 54)Ph.D., Co-Founder & Chairman of Scientific Advisory Board Comp: $1.4MMr. Cameron Peters (Age 64)Vice President of Finance, Assistant Treasurer & Principal Accounting Officer Ms. Elhan Webb C.F.A.Senior Vice President of Investor RelationsMr. Michael J. Mano J.D. (Age 47)Senior VP, General Counsel & Secretary Comp: $625.08kMr. James Accumanno J.D.Chief Compliance OfficerMore ExecutivesKey CompetitorsVistagen TherapeuticsNASDAQ:VTGNAbeona TherapeuticsNASDAQ:ABEOImmunicNASDAQ:IMUXNuvectis PharmaNASDAQ:NVCTCartesian TherapeuticsNASDAQ:RNACView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 371,757 shares on 5/10/2024Ownership: 7.160%Richard A PaulsonSold 3,576 sharesTotal: $4,040.88 ($1.13/share)GSA Capital Partners LLPSold 1,038,834 shares on 5/3/2024Ownership: 1.115%Simplicity Wealth LLCBought 44,011 shares on 4/24/2024Ownership: 0.038%Reshma RangwalaSold 6,789 sharesTotal: $7,943.13 ($1.17/share)View All Insider TransactionsView All Institutional Transactions KPTI Stock Analysis - Frequently Asked Questions Should I buy or sell Karyopharm Therapeutics stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KPTI shares. View KPTI analyst ratings or view top-rated stocks. What is Karyopharm Therapeutics' stock price target for 2024? 5 analysts have issued 1 year price targets for Karyopharm Therapeutics' stock. Their KPTI share price targets range from $3.00 to $8.00. On average, they predict the company's stock price to reach $4.80 in the next twelve months. This suggests a possible upside of 328.6% from the stock's current price. View analysts price targets for KPTI or view top-rated stocks among Wall Street analysts. How have KPTI shares performed in 2024? Karyopharm Therapeutics' stock was trading at $0.8650 at the beginning of 2024. Since then, KPTI stock has increased by 29.5% and is now trading at $1.12. View the best growth stocks for 2024 here. When is Karyopharm Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our KPTI earnings forecast. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced its quarterly earnings results on Thursday, February, 29th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.07. The business earned $33.75 million during the quarter, compared to the consensus estimate of $33.50 million. During the same quarter in the prior year, the company posted ($0.43) EPS. What guidance has Karyopharm Therapeutics issued on next quarter's earnings? Karyopharm Therapeutics issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $140.0 million-$160.0 million, compared to the consensus revenue estimate of $146.5 million. What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO? 31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees. What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY). Who are Karyopharm Therapeutics' major shareholders? Karyopharm Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.16%), GSA Capital Partners LLP (1.12%) and Simplicity Wealth LLC (0.04%). Insiders that own company stock include Deepika Pakianathan, Garen G Bohlin, Jatin Shah, Michael Kauffman, Michael Mano, Michael Mason, Reshma Rangwala, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener and Stuart Poulton. View institutional ownership trends. How do I buy shares of Karyopharm Therapeutics? Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KPTI) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressNo experience to confident trader, meet my student…Wealth Builders InstituteThe only AI company you should be looking atBehind the MarketsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
